Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220
Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Brand Name : RC220
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?